Expanded Disability Status Scale (EDSS)
Quantifies neurological disability in MS patients on a 0-10 scale. Used to monitor disease progression and guide disease-modifying therapy decisions.
Score interpretation
→ High-efficacy DMT for active RRMS (natalizumab, ocrelizumab, alemtuzumab); or moderate-efficacy (interferon, GA, teriflunomide); annual MRI; lifestyle: exercise, vitamin D, smoking cessation
→ Reassess DMT efficacy; escalate if breakthrough disease; physiotherapy; bladder management; fatigue management; occupational therapy; maintain highest possible function
→ Symptomatic management priority; spasticity (baclofen, botulinum); bladder (oxybutynin, ISC); pain (amitriptyline, gabapentin); wheelchair assessment; carer support; palliative input if EDSS >=9
Interpretation bands for the EDSS Score. Apply clinical judgement and local guidance.
References
Related
Curated clinical cross-links plus same-class fallbacks.
- Dimethyl Fumarate · Disease-Modifying Therapy — Relapsing-Remitting Multiple Sclerosis
- Ocrelizumab · Multiple Sclerosis — Disease-Modifying Therapy
- Fingolimod · Multiple Sclerosis — Disease-Modifying Therapy
- Alemtuzumab · Multiple Sclerosis — Disease-Modifying Therapy
- Cladribine · Multiple Sclerosis — Disease-Modifying Therapy
- Ofatumumab · Multiple Sclerosis — Disease-Modifying Therapy
- Acute Stroke / TIA Assessment · NICE NG128; RCP Stroke Guidelines 2023
- Status Epilepticus (Adults) · NICE CG137; ESEM guidelines; RCP Neurology Guidelines
- Suspected Subarachnoid Haemorrhage · NICE NG228; RCEM 2023; AHA/ASA 2023
- Adult Head Injury · NICE NG232 (2023)
- Bell's Palsy / Facial Nerve Palsy · ENT UK 2017; AAN
- Vertigo Workup · ENT UK; NICE CKS
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.